JP2025503971A5 - - Google Patents
Info
- Publication number
- JP2025503971A5 JP2025503971A5 JP2024544447A JP2024544447A JP2025503971A5 JP 2025503971 A5 JP2025503971 A5 JP 2025503971A5 JP 2024544447 A JP2024544447 A JP 2024544447A JP 2024544447 A JP2024544447 A JP 2024544447A JP 2025503971 A5 JP2025503971 A5 JP 2025503971A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- pharmaceutically acceptable
- mta
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303497P | 2022-01-26 | 2022-01-26 | |
| US63/303,497 | 2022-01-26 | ||
| PCT/US2023/011658 WO2023146989A1 (en) | 2022-01-26 | 2023-01-26 | Compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503971A JP2025503971A (ja) | 2025-02-06 |
| JP2025503971A5 true JP2025503971A5 (cg-RX-API-DMAC7.html) | 2026-02-16 |
Family
ID=85382515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544447A Pending JP2025503971A (ja) | 2022-01-26 | 2023-01-26 | 化合物及び使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250171432A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4469447A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503971A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023146989A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025504916A (ja) * | 2022-01-26 | 2025-02-19 | タンゴ セラピューティクス, インコーポレイテッド | 化合物及び使用方法 |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
| CN118359607A (zh) * | 2023-01-17 | 2024-07-19 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| WO2024213044A1 (en) * | 2023-04-14 | 2024-10-17 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Azacyclo-carbonyl-fused ring derivatives and use thereof |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2025217297A1 (en) | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| CN116568677B (zh) * | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| IL308853A (en) * | 2021-06-02 | 2024-01-01 | Ideaya Biosciences Inc | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| CN117658980A (zh) * | 2022-09-08 | 2024-03-08 | 郑州同源康医药有限公司 | 双环类prmt5抑制剂 |
-
2023
- 2023-01-26 EP EP23707536.1A patent/EP4469447A1/en active Pending
- 2023-01-26 US US18/833,486 patent/US20250171432A1/en active Pending
- 2023-01-26 WO PCT/US2023/011658 patent/WO2023146989A1/en not_active Ceased
- 2023-01-26 JP JP2024544447A patent/JP2025503971A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7190549B2 (ja) | Hdac阻害剤とpd-1阻害剤との組み合わせ療法 | |
| JP7190548B2 (ja) | Hdac阻害剤とpd-l1阻害剤との組み合わせ療法 | |
| Li et al. | HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers | |
| Barroso-Sousa et al. | Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond: R. Barroso-Sousa et al. | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| Jimeno et al. | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer | |
| Gainor et al. | Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non–small cell lung cancer relapsing on standard dose alectinib | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| US20120130144A1 (en) | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor | |
| JP2019501204A5 (cg-RX-API-DMAC7.html) | ||
| WO2021183318A2 (en) | Methods and compositions relating to improved combination therapies | |
| JP2018508469A5 (cg-RX-API-DMAC7.html) | ||
| JP2019507721A5 (cg-RX-API-DMAC7.html) | ||
| JP2020535173A5 (cg-RX-API-DMAC7.html) | ||
| JP2020505433A5 (cg-RX-API-DMAC7.html) | ||
| WO2020078905A1 (en) | Combination therapy utilizing dna alkylating agents and atr inhibitors | |
| WO2022031952A9 (en) | Treatments for cancers having kras mutations | |
| TW202537643A (zh) | 抗體-藥物結合物之用途 | |
| JP2016530273A (ja) | 癌を治療するためのhdac8阻害剤 | |
| RU2017146346A (ru) | Комбинированная терапия pac-1 | |
| JP2025540925A (ja) | 癌の治療におけるアゼノセルチブの断続的投与レジメン | |
| JP2021519302A5 (cg-RX-API-DMAC7.html) | ||
| EP3793564A1 (en) | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma | |
| JP2018537519A5 (cg-RX-API-DMAC7.html) | ||
| Chakraborty et al. | AZD4625 is a potent and selective inhibitor of KRASG12C |